Adma Biologics Inc. (NASDAQ:ADMA)’s share price rose 7.8% on Tuesday . The company traded as high as $7.33 and last traded at $7.33, with a volume of 56,382 shares traded. The stock had previously closed at $6.80.

Separately, Maxim Group reiterated a “buy” rating and issued a $24.00 price target on shares of Adma Biologics in a research report on Thursday, March 24th.

The stock’s market capitalization is $94.33 million. The firm has a 50-day moving average price of $7.00 and a 200-day moving average price of $6.45.

Adma Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Friday, May 13th. The company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by $0.06. Equities research analysts anticipate that Adma Biologics Inc. will post ($1.03) EPS for the current year.

In other Adma Biologics news, Director Jerrold B. Grossman purchased 45,769 shares of Adma Biologics stock in a transaction on Tuesday, May 3rd. The stock was bought at an average cost of $6.50 per share, with a total value of $297,498.50. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Adam S. Grossman purchased 200,000 shares of Adma Biologics stock in a transaction on Tuesday, May 3rd. The shares were acquired at an average cost of $6.50 per share, with a total value of $1,300,000.00. The disclosure for this purchase can be found here.

ADMA Biologics, Inc is a biopharmaceutical company that develops and manufactures specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. The company’s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.